

DR. CHIARA FABBRONI

Personal Information:

Data and Place of Birth September 29th 1988, Arezzo, Italy

Current Address:

E-mail:

Phone/Fax:

Education:

- 04 Nov '20 **Medical Oncology degree at University of Milan.** Final dissertation: "Trabectedin in well differentiated/dedifferentiated liposarcoma: impact of the grade of dedifferentiation."
- 01 Nov '18 – 31 Oct '20 **Residency in Medical Oncology** at Dept of Mesenchymal Tumors of adults and Rare Tumors - Medical Oncology 2, Fondazione IRCCS Istituto Nazionale Tumori, Via G. Venezian 1, 20133 - Milano, Italy
Director: Prof. Paolo G. CASALI
- 01 Nov '17 – 31 Oct '18 **Residency in Medical Oncology** at Dept of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Via G. Venezian 1, 20133 - Milano, Italy
Director: Prof. Filippo DE BRAUD
- 01 Nov '15 – 30 Oct '17 **Residency in Medical Oncology** at Department of Medical Oncology, Ospedale Policlinico San Martino IRCCS per l'Oncologia, Largo R. Benzi 10, 16132 - Genova, Italy
Director: Prof. Francesco BOCCARDO
- 5 Feb '14 **National Board Certified for Clinical Practice**
- 18 Oct '13 **Medical and Surgical degree.** 108/110. School of Medicine: University of Florence, Italy. Final dissertation: "Locally advanced and metastatic pancreatic cancer: a single institution experience of a series of patients treated with FOLFIRINOX regimen."
- 9 Jul '07 **High School Diploma.** Liceo Classico F. Petrarca, Arezzo, Italy.

Professional Experience and Training:

- 01 Nov '18 – 31 Oct '20 Experience in sarcoma board and clinical case discussion within national Italian rare cancers network.
- 01 Nov '15 – 30 Oct '17 Experience in genitourinary cancers and experience in case discussion in Genitourinary tumor board.
- Mar '14 – Mar '15 **Doctor for Emergency medical care** and substitution as **general practitioner** at ASL 8 – Arezzo, Italy

- Sept '11 – Sept '13 **Experience** in Medical Oncology at Department of Medical Oncology, AOU Careggi, University of Florence, Italy. Director: Prof. F. Di Costanzo
- Oct '08 – Apr '11 **Basic Life Support Defibrillation (BLSD) Licence** and activity as a **trained first responder** at Public Assistance Humanitas Firenze nord, Italy.

Languages

Italian: Native
English: Fluent
French: Basic level

Memberships:

European Society for Medical Oncology (ESMO) from Feb '16
Associazione Italiana di Oncologia Medica (AIOM) from Feb'16

Publications:

- Cattrini C, Zanardi E, Vallome G, Cavo A, Cerbone L, Di meglio A, Fabbroni C, Lattoca MM, Rizzo F, Messina C, Rubagotti A, Barboro P, Boccardo F. Targeting androgen-independent pathways: new chances for patients with prostate cancer? *Crit Rev Oncol Hematol* 2017;118:42-53
- Celio L, Fabbroni C. Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting *Expert Opin Pharmacother* 2018; 11:1267-1277
- Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Arboscello E, Bellodi A, Spallarossa P, Boccardo F. Abiraterone Acetate and prednisone in pre- and post-docetaxel setting for metastatic castration resistant prostate cancer: a monoinstitutional experience focused on cardiovascular events and their impact on clinical outcomes. *Ther Adv Med Oncol*. 2018; 9,10.
- Vernieri C, Prisciandaro M, Milano M, Cona MS, Maggi C, Brambilla M, Mennitto A, Fabbroni C, Farè E, Cresta S, Celio L, Mariani G, Bianchi G, Capri G, De Braud F. Single-agent gemcitabine versus carboplatin-gemcitabine in advanced breast cancer: a retrospective comparison of efficacy and safety profiles. *J Clinical Breast Cancer* 2019; 2:e306-e318.
- Vernieri C, Milano M, Mariani G, Maggi C, Cona MS, Fabbroni C, Brambilla M, Bianchi G, Celio L, Capri G, Mennitto A, Prisciandaro M, De Braud F. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives. *J Critical Reviews in Oncology/Hematology* 2019
- Fabbroni C, Sbaraglia M, Sanfilippo Medical treatment of advanced malignant perivascular epithelioid cell tumors. *R.Curr Opin Oncol*. 2020

Sanfilippo R, Fabbroni C, Fucà G, Fumagalli E, Morosi C, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. Clin Cancer Res. 2020

Fucà G, Fabbroni C, Mancari R, Manglaviti S, Bogani G, Fumagalli E, Bertulli R, Morosi C, Collini P, Raspagliesi F, Colombo N, Casali PG, Sanfilippo R. Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers. Clin Sarcoma Res. 2020

Posters, oral presentations and chapters

Boccardo F, Cavo A, Zanardi E, Fabbroni C, Zinoli L, Di meglio A, Arboscello E, Bellodi A, Spallarossa P, Cattrini C, Messina C, Rubagotti A. Abiraterone Acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes. Poster Session ESMO Congress 2017

Sanfilippo R., Fabbroni C., E. Fumagalli¹, et al. 5450 - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa. ESMO congress 2019

Zattarin E., Fabbroni C. Ligorio F et al 32P The neutrophil-to-lymphocyte ratios predict efficacy of CDK4/6 inhibitors in women with hormone receptor-positive/HER2-negative advanced breast cancer jannonc 2020

12 Giugno 2019 Catania Percorsi assistenziali nel trattamento dei sarcomi dei tessuti molli metastatici in Sicilia: stato dell'arte e nuovi sviluppi Lettura: *Trabectedina cosa abbiamo imparato ad oggi e quali prospettive future*

Sanfilippo R, Fabbroni C, Dei Tos P, Gronchi A. Myxoid Liposarcoma in *Sarcomas Evidence-based diagnosis and management*. ISBN-13: 978-0826148520

Experience in clinical trial

Sub-investigator for: A phase IIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole (BioItaLEE)

Sub-investigator for: Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6/12 months of last platinum (INOVATYON)

Sub-investigator for: A prospective observational study of patients with metastatic castration resistant prostate cancer progressing after standard hormonal therapy suitable for abiraterone acetate treatment (ABITUDE)

Sub-investigator for: A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab* (Msb0010718c) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-Line Platinum-Containing Chemotherapy

Congress

03-05 Feb 2020, Milan ESMO Sarcoma and GIST 2020

29 Nov-01 Dec 2019 4th ESO-ESMO-RCE Clinical update on rare adult solid cancers

27 Sep-1 Oct 2019, Barcelona - ESMO Congress

03-05 July 2019, Residential Course - Clinical Oncology: Sarcomas, Inveruno,

4-6 Apr 2019, Pisa, Italian Sarcoma Group XXIII Riunione ISG

23-28 Mar 2019, Nauen OT Gross Berhnitz, 18th ESO-ESMO Masterclass in Clinical oncology

13-15 Dec 2018 Genova, Grandangolo 2018

1-3 Dec 2018, Milan, 3rd ESO-ESMO-RCE Preceptorship and Clinical Update on Rare Adult Solid Cancers

21-22 Apr 2017, Prague, Czech Republic ESMO Preceptorship on Ovarian Cancer

Milan 04/11/2020

Chiara Fabbroni

4

Fondazione IRCCS
Istituto Nazionale dei Tumori
Dott. Paolo G. Casali
C.F. CSL.PGV 581281531C

sta bene